Grass pollen allergy immunotherapy low dose - ALK-Abello

Drug Profile

Grass pollen allergy immunotherapy low dose - ALK-Abello

Alternative Names: Avanz; Grass pollen allergy vaccine - ALK-Abello

Latest Information Update: 01 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ALK-Abello
  • Class Allergens; Antiallergics; Plant allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Allergic rhinoconjunctivitis

Most Recent Events

  • 01 Oct 2015 ALK-Abelló completes a phase II trial in Allergic rhinoconjunctivitis in Germany (NCT02166268)
  • 24 Apr 2012 ALK-Abelló completes a phase II/III trial in Allergic rhinoconjunctivitis in Spain (NCT01454531)
  • 10 Feb 2012 ALK-Abelló completes enrolment in its phase II/III trial for Allergic rhinoconjunctivitis in Austria, Germany and Spain (NCT01438827)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top